Literature DB >> 760380

The relationship between the cytotoxicity of kanamycin and ethacrynic acid for mammalian cells in vitro and their ototoxicity in vivo.

K E Fox, R E Brummett.   

Abstract

Dose-effect curves for inhibition of growth of P388/P mouse lymphoma cells by ethacrynic acid and kanamycin used alone and in combination were determined in vitro. Ethacrynic acid was 600 times more potent than kanamycin and combinations of the drugs resulted in overall additive effects. These results were compared with known dose-effect data on the ototoxicity of these drugs in vivo. Kanamycin was highly selective in its toxicity for cochlear hair cells compared to cultured cells. The dose-effect data for ethacrynic acid was coincident with that reported for functional and biochemical effects on the cochlea following perilymphatic perfusion with the drug. The potentiation observed following the ototoxic interaction the two drugs in vivo was not observed following combinations of the drugs in vitro.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760380     DOI: 10.3109/00016487909126389

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  4 in total

1.  Simultaneous investigations of elemental changes in individual cells of the stria vascularis and in endolymph.

Authors:  M Anniko; R Wróblewski
Journal:  Arch Otorhinolaryngol       Date:  1988

2.  Ototoxicity or teratogenicity. An analysis of drug-induced effects on the early development of the mammalian otocyst.

Authors:  M Anniko; H Nordemar
Journal:  Arch Otorhinolaryngol       Date:  1981

3.  Uptake of fluorescent gentamicin by vertebrate sensory cells in vivo.

Authors:  C F Dai; D Mangiardi; D A Cotanche; P S Steyger
Journal:  Hear Res       Date:  2006-02-08       Impact factor: 3.208

Review 4.  Drug-induced ototoxicity. Pathogenesis and prevention.

Authors:  M Y Huang; J Schacht
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.